analgesic preparations; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of infla Read More

Classification Information

Class [005]
Analgesic preparations; Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical preparations for the treatment of inflammation; Pharmaceutical preparations for the treatment of Dupuytren's disease; Pharmaceutical preparations for the treatment of frozen shoulder; Pharmaceutical preparations for the treatment of post-operative delirium; Pharmaceutical preparations for the treatment of post-operative cognitive deficit; Pharmaceutical preparations for the treatment of post-operative cognitive decline; Pharmaceutical preparations for the treatment of n on-alcoholic steatohepatitis; Pharmaceutical preparations for the treatment of fibrosis; Pharmaceutical preparations for the treatment of liver fibrosis; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of ulcerative colitis; Pharmaceutical preparations for the treatment of anxiety; Pharmaceutical preparations for the treatment of type 1 diabetes; Pharmaceutical preparations for the treatment of type 2 diabetes; Pharmaceutical preparations for inhibition of tumor necrosis factor (TNF); Pharmaceutical preparations for interacting with nicotine receptors; Pharmaceutical preparations for synthetically simulating non-psychoactive effects of cannabidiol (CBD); Pharmaceutical preparations for liver regeneration; Pharmaceutical preparations for regenerative therapy; Pharmaceutical preparations for acting as an alpha-7nAChR agonist

Classification kind code

Class [042]
Development of pharmaceutical preparations and medicines; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research and development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development in the pharmaceutical and biotechnology fields; Scientific research for medical purposes in the field of inflammatory diseases; Scientific research for medical purposes in the field of treatment of inflammation; Scientific research for medical purposes in the field of Dupuytren's disease; Scientific research for medical purposes in the field of frozen shoulder; Scientific research for medical purposes in the field of post-operative delirium, post-operative cognitive deficit, and post-operative cognitive decline; Scientific research for medical purposes in the field of non-alcoholic steatohepatitis; Scientific research for medical purposes in the field of fibrosis; Scientific research for medical purposes in the field of liver fibrosis; Scientific research for medical purposes in the field of arthritis; Scientific research for medical purposes in the field of pain treatment ; Scientific research for medical purposes in the field of ulcerative colitis; Scientific research for medical purposes in the field of treatment of anxiety; Scientific research for medical purposes in the field of inhibition of tumor necrosis factor (TNF) and anti-TNF pharmaceuticals; Scientific research for medical purposes in the field of interactions with nicotine receptors; Scientific research for medical purposes in the field of synthetic simulation of non-psychoactive effects of cannabidiol (CBD); Scientific research for medical purposes in the field of synthetic cannabidiol (CBD) analogs; Scientific research for medical purposes in the field of type 1 diabetes; Scientific research for medical purposes in the field of type 2 diabetes; Scientific research for medical purposes in the field of liver regeneration; Scientific research for medical purposes in the field of regenerative therapy; Scientific research for medical purposes in the field of alpha-7nAChR agonists

Classification kind code

Mark Details

Serial Number

2202334

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 67 on 07^th Oct 2022	Agent Name Changed
Submitted for opposition 287 on 11^th Aug 2022	Pre-Assessment Letter Sent
Submitted for opposition 30 on 04^th Aug 2022	Filed
Submitted for opposition 1 on 04^th Aug 2022	Created
Submitted for opposition 31 on 04^th Aug 2022	Formalized